BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 24149930)

  • 1. Phase 3 randomized controlled study of gastroretentive gabapentin for the treatment of moderate-to-severe hot flashes in menopause.
    Pinkerton JV; Kagan R; Portman D; Sathyanarayana R; Sweeney M;
    Menopause; 2014 Jun; 21(6):567-73. PubMed ID: 24149930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastroretentive gabapentin (G-GR) formulation reduces intensity of pain associated with postherpetic neuralgia (PHN).
    Sang CN; Sathyanarayana R; Sweeney M;
    Clin J Pain; 2013 Apr; 29(4):281-8. PubMed ID: 22801243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gabapentin for the treatment of menopausal hot flashes: a randomized controlled trial.
    Butt DA; Lock M; Lewis JE; Ross S; Moineddin R
    Menopause; 2008; 15(2):310-8. PubMed ID: 17917611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gabapentin for the treatment of hot flashes in women with natural or tamoxifen-induced menopause: a systematic review and meta-analysis.
    Toulis KA; Tzellos T; Kouvelas D; Goulis DG
    Clin Ther; 2009 Feb; 31(2):221-35. PubMed ID: 19302896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of gabapentin for the management of natural or surgical menopausal hot flashes.
    Hayes LP; Carroll DG; Kelley KW
    Ann Pharmacother; 2011 Mar; 45(3):388-94. PubMed ID: 21343402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial.
    Pandya KJ; Morrow GR; Roscoe JA; Zhao H; Hickok JT; Pajon E; Sweeney TJ; Banerjee TK; Flynn PJ
    Lancet; 2005 Sep 3-9; 366(9488):818-24. PubMed ID: 16139656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial.
    Reddy SY; Warner H; Guttuso T; Messing S; DiGrazio W; Thornburg L; Guzick DS
    Obstet Gynecol; 2006 Jul; 108(1):41-8. PubMed ID: 16816054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-daily gastroretentive gabapentin for postherpetic neuralgia: integrated efficacy, time to onset of pain relief and safety analyses of data from two phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
    Rauck RL; Irving GA; Wallace MS; Vanhove GF; Sweeney M
    J Pain Symptom Manage; 2013 Aug; 46(2):219-28. PubMed ID: 23149085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A gastroretentive gabapentin formulation for the treatment of painful diabetic peripheral neuropathy: efficacy and tolerability in a double-blind, randomized, controlled clinical trial.
    Sandercock D; Cramer M; Biton V; Cowles VE
    Diabetes Res Clin Pract; 2012 Sep; 97(3):438-45. PubMed ID: 22497967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of gabapentin in patients experiencing hot flashes.
    Brown JN; Wright BR
    Pharmacotherapy; 2009 Jan; 29(1):74-81. PubMed ID: 19113798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of once-daily gastroretentive gabapentin in patients with postherpetic neuralgia aged 75 years and over.
    Gupta A; Li S
    Drugs Aging; 2013 Dec; 30(12):999-1008. PubMed ID: 24163280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Steady-state pharmacokinetics of gabapentin after administration of a novel gastroretentive extended-release formulation in postmenopausal women with vasomotor symptoms.
    Cowles VE; Gordi T; Hou SY
    Clin Drug Investig; 2012 Sep; 32(9):593-601. PubMed ID: 22775354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia.
    Parsons B; Tive L; Huang S
    Am J Geriatr Pharmacother; 2004 Sep; 2(3):157-62. PubMed ID: 15561647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of gabapentin on sleep in menopausal women with hot flashes as measured by a Pittsburgh Sleep Quality Index factor scoring model.
    Yurcheshen ME; Guttuso T; McDermott M; Holloway RG; Perlis M
    J Womens Health (Larchmt); 2009 Sep; 18(9):1355-60. PubMed ID: 19708803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety of gastroretentive gabapentin in postherpetic neuralgia patients.
    Jensen MP; Irving G; Rauck R; Wallace M; Sweeney M; Vanhove GF
    Clin J Pain; 2013 Sep; 29(9):770-4. PubMed ID: 23370075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-hormonal treatment of hot flushes in breast cancer survivors: gabapentin vs. vitamin E.
    Biglia N; Sgandurra P; Peano E; Marenco D; Moggio G; Bounous V; Tomasi Cont N; Ponzone R; Sismondi P
    Climacteric; 2009 Aug; 12(4):310-8. PubMed ID: 19415540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: a 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trial.
    Pinkerton JV; Constantine G; Hwang E; Cheng RF;
    Menopause; 2013 Jan; 20(1):28-37. PubMed ID: 23010882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of partial seizures with gabapentin: double-blind, placebo-controlled, parallel-group study.
    Yamauchi T; Kaneko S; Yagi K; Sase S
    Psychiatry Clin Neurosci; 2006 Aug; 60(4):507-15. PubMed ID: 16884455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gabapentin vs. low-dose transdermal estradiol for treating post-menopausal women with moderate to very severe hot flushes.
    Aguirre W; Chedraui P; Mendoza J; Ruilova I
    Gynecol Endocrinol; 2010 May; 26(5):333-7. PubMed ID: 20050764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gabapentin for the management of hot flashes in prostate cancer survivors: a longitudinal continuation Study-NCCTG Trial N00CB.
    Moraska AR; Atherton PJ; Szydlo DW; Barton DL; Stella PJ; Rowland KM; Schaefer PL; Krook J; Bearden JD; Loprinzi CL
    J Support Oncol; 2010; 8(3):128-32. PubMed ID: 20552926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.